1887

Abstract

Porcine reproductive and respiratory syndrome virus (PRRSV) is one of the most devastating pathogens to the global swine industry. Many commercial PRRSV vaccines, originally designed to provide homologous protection, have shown partial protection against heterologous strains. However, the protective immune mechanisms mediated by these PRRSV vaccines are not fully understood. In this study, we investigated the factors responsible for partial protection conferred by an attenuated Chinese HP-PRRSV vaccine (TJM-F92) against heterologous NADC30-like PRRSV. By analysing peripheral T-cell responses induced by the TJM-F92 vaccine and local and systemic memory responses following challenge with NADC30-like PRRSV (SD17-38 strains) as well as neutralizing antibody response, we found that the TJM-F92 vaccine induced a significant expansion of CD8 T cells but not CD4 T cells or γδ T cells. The expanded CD8 T cells exhibited a phenotype of effector memory T cells and secreted IFN-γ upon restimulation with SD17-38 strains . In addition, only CD8 T cells in the prior immunized pigs rapidly expanded in the blood and spleen after heterologous challenge, with higher magnitude, compared to the unvaccinated pigs, showing a remarkable memory response. In contrast, no obvious humoral immune response was enhanced in the vaccinated and challenged pigs, and no heterologous neutralizing antibodies were detected throughout the experiment. Our results suggested that CD8 T cells elicited by the TJM-F92 vaccine may be responsible for partial heterologous protection against NADC30-like PRRSV strains and potentially recognize the conserved antigens among PRRSV strains.

Funding
This study was supported by the:
  • This study was financially supported by The National Key Research and Development Program of China (2022YFD1800300) and State Key Laboratory of Genetically Engineered Veterinary Vaccines(AGVSKL-ZD-202006), and the Priority Academic Programme Developmentof Jiangsu Higher Education Institutions (PAPD).
    • Principle Award Recipient: ShangShaobin
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001850
2023-05-09
2024-11-06
Loading full text...

Full text loading...

References

  1. Cavanagh D. Nidovirales: a new order comprising Coronaviridae and Arteriviridae. Arch Virol 1997; 142:629–633 [PubMed]
    [Google Scholar]
  2. Stoian AMM, Rowland RRR. Challenges for Porcine Reproductive and Respiratory Syndrome (PRRS) vaccine design: reviewing virus glycoprotein interactions with CD163 and targets of virus neutralization. Vet Sci 2019; 6:9 [View Article] [PubMed]
    [Google Scholar]
  3. Shi M, Lam TT-Y, Hon C-C, Murtaugh MP, Davies PR et al. Phylogeny-based evolutionary, demographical, and geographical dissection of North American type 2 porcine reproductive and respiratory syndrome viruses. J Virol 2010; 84:8700–8711 [View Article]
    [Google Scholar]
  4. Shi M, Lam TT-Y, Hon C-C, Hui RK-H, Faaberg KS et al. Molecular epidemiology of PRRSV: a phylogenetic perspective. Virus Res 2010; 154:7–17 [View Article] [PubMed]
    [Google Scholar]
  5. Zhou L, Yang H. Porcine reproductive and respiratory syndrome in China. Virus Research 2010; 154:31–37 [View Article]
    [Google Scholar]
  6. Tian K, Yu X, Zhao T, Feng Y, Cao Z et al. Emergence of fatal PRRSV variants: unparalleled outbreaks of atypical PRRS in China and molecular dissection of the unique hallmark. PLoS One 2007; 2:e526 [View Article] [PubMed]
    [Google Scholar]
  7. Chae C. Commercial PRRS modified-live virus vaccines. Vaccines 2021; 9:185 [View Article]
    [Google Scholar]
  8. Leng X, Li Z, Xia M, He Y, Wu H. Evaluation of the efficacy of an attenuated live vaccine against highly pathogenic porcine reproductive and respiratory syndrome virus in young pigs. Clin Vaccine Immunol 2012; 19:1199–1206 [View Article] [PubMed]
    [Google Scholar]
  9. Wei Z, Zhang J, Zhuang J, Sun Z, Gao F et al. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a deadly long lasting hyperpyrexia in a challenge study with highly pathogenic PRRSV JX143. Vaccine 2013; 31:2062–2066 [View Article]
    [Google Scholar]
  10. Bai X, Wang Y, Xu X, Sun Z, Xiao Y et al. Commercial vaccines provide limited protection to NADC30-like PRRSV infection. Vaccine 2016; 34:5540–5545 [View Article]
    [Google Scholar]
  11. Zhou L, Yang B, Xu L, Jin H, Ge X et al. Efficacy evaluation of three modified-live virus vaccines against a strain of porcine reproductive and respiratory syndrome virus NADC30-like. Vet Microbiol 2017; 207:108–116 [View Article] [PubMed]
    [Google Scholar]
  12. Sun Y-F, Zhou L, Bian T, Tian X-X, Ren W-K et al. Efficacy evaluation of two commercial modified-live virus vaccines against a novel recombinant type 2 porcine reproductive and respiratory syndrome virus. Vet Microbiol 2018; 216:176–182 [View Article]
    [Google Scholar]
  13. Chai W, Liu Z, Sun Z, Su L, Zhang C et al. Efficacy of two porcine reproductive and respiratory syndrome (PRRS) modified-live virus (MLV) vaccines against heterologous NADC30-like PRRS virus challenge. Vet Microbiol 2020; 248:108805 [View Article] [PubMed]
    [Google Scholar]
  14. Lopez OJ, Osorio FA. Role of neutralizing antibodies in PRRSV protective immunity. Vet Immunol Immunopathol 2004; 102:155–163 [View Article] [PubMed]
    [Google Scholar]
  15. Vanhee M, Delputte PL, Delrue I, Geldhof MF, Nauwynck HJ. Development of an experimental inactivated PRRSV vaccine that induces virus-neutralizing antibodies. Vet Res 2009; 40:63 [View Article] [PubMed]
    [Google Scholar]
  16. Osorio FA, Galeota JA, Nelson E, Brodersen B, Doster A et al. Passive transfer of virus-specific antibodies confers protection against reproductive failure induced by a virulent strain of porcine reproductive and respiratory syndrome virus and establishes sterilizing immunity. Virology 2002; 302:9–20 [View Article] [PubMed]
    [Google Scholar]
  17. Chen N, Li S, Tian Y, Li X, Li S et al. Chimeric HP-PRRSV2 containing an ORF2-6 consensus sequence induces antibodies with broadly neutralizing activity and confers cross protection against virulent NADC30-like isolate. Vet Res 2021; 52:74 [View Article] [PubMed]
    [Google Scholar]
  18. Sun H, Workman A, Osorio FA, Steffen D, Vu HLX. Development of a broadly protective modified-live virus vaccine candidate against porcine reproductive and respiratory syndrome virus. Vaccine 2018; 36:66–73 [View Article]
    [Google Scholar]
  19. Lunney JK, Fang Y, Ladinig A, Chen N, Li Y et al. Porcine Reproductive and Respiratory Syndrome Virus (PRRSV): pathogenesis and interaction with the immune system. Annu Rev Anim Biosci 2016; 4:129–154 [View Article] [PubMed]
    [Google Scholar]
  20. Rahe MC, Murtaugh MP. Mechanisms of adaptive immunity to porcine reproductive and respiratory syndrome virus. Viruses 2017; 9:148 [View Article] [PubMed]
    [Google Scholar]
  21. Park C, Seo HW, Han K, Kang I, Chae C. Evaluation of the efficacy of a new modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine (Fostera PRRS) against heterologous PRRSV challenge. Vet Microbiol 2014; 172:432–442 [View Article] [PubMed]
    [Google Scholar]
  22. Zhang H, Xia M, Wang W, Ju D, Cao L et al. An attenuated highly pathogenic Chinese PRRS viral vaccine confers cross protection to pigs against challenge with the emerging PRRSV NADC30-like strain. Virol Sin 2018; 33:153–161 [View Article]
    [Google Scholar]
  23. Loving CL, Osorio FA, Murtaugh MP, Zuckermann FA. Innate and adaptive immunity against porcine reproductive and respiratory syndrome virus. Vet Immunol Immunopathol 2015; 167:1–14 [View Article] [PubMed]
    [Google Scholar]
  24. Bocard LV, Kick AR, Hug C, Lischer HEL, Käser T et al. Systems immunology analyses following porcine respiratory and reproductive syndrome virus infection and vaccination. Front Immunol 2021; 12:779747 [View Article] [PubMed]
    [Google Scholar]
  25. Xiao Z, Batista L, Dee S, Halbur P, Murtaugh MP. The level of virus-specific T-cell and macrophage recruitment in porcine reproductive and respiratory syndrome virus infection in pigs is independent of virus load. J Virol 2004; 78:5923–5933 [View Article]
    [Google Scholar]
  26. Kick AR, Amaral AF, Cortes LM, Fogle JE, Crisci E et al. The T-cell response to type 2 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). Viruses 2019; 11:796 [View Article] [PubMed]
    [Google Scholar]
  27. Ferrari L, Martelli P, Saleri R, De Angelis E, Cavalli V et al. Lymphocyte activation as cytokine gene expression and secretion is related to the porcine reproductive and respiratory syndrome virus (PRRSV) isolate after in vitro homologous and heterologous recall of peripheral blood mononuclear cells (PBMC) from pigs vaccinated and exposed to natural infection. Vet Immunol Immunopathol 2013; 151:193–206 [View Article] [PubMed]
    [Google Scholar]
  28. Olin MR, Batista L, Xiao Z, Dee SA, Murtaugh MP et al. Gammadelta lymphocyte response to porcine reproductive and respiratory syndrome virus. Viral Immunol 2005; 18:490–499 [View Article] [PubMed]
    [Google Scholar]
  29. Cao QM, Tian D, Heffron CL, Subramaniam S, Opriessnig T et al. Cytotoxic T lymphocyte epitopes identified from a contemporary strain of porcine reproductive and respiratory syndrome virus enhance CD4+CD8+ T, CD8+ T, and γδ T cell responses. Virology 2019; 538:35–44 [View Article] [PubMed]
    [Google Scholar]
  30. Chung CJ, Cha S-H, Grimm AL, Ajithdoss D, Rzepka J et al. Pigs that recover from porcine reproduction and respiratory syndrome virus infection develop cytotoxic CD4+CD8+ and CD4+CD8- T-cells that kill virus infected cells. PLoS One 2018; 13:e0203482 [View Article] [PubMed]
    [Google Scholar]
  31. Mateu E, Diaz I. The challenge of PRRS immunology. Vet J 2008; 177:345–351 [View Article]
    [Google Scholar]
  32. Díaz I, Darwich L, Pappaterra G, Pujols J, Mateu E. Different European-type vaccines against porcine reproductive and respiratory syndrome virus have different immunological properties and confer different protection to pigs. Virology 2006; 351:249–259 [View Article] [PubMed]
    [Google Scholar]
  33. Albina E, Piriou L, Hutet E, Cariolet R, L’Hospitalier R. Immune responses in pigs infected with Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). Vet Immunol Immunopathol 1998; 61:49–66 [View Article] [PubMed]
    [Google Scholar]
  34. Dwivedi V, Manickam C, Binjawadagi B, Linhares D, Murtaugh MP et al. Evaluation of immune responses to porcine reproductive and respiratory syndrome virus in pigs during early stage of infection under farm conditions. Virol J 2012; 9:45 [View Article] [PubMed]
    [Google Scholar]
  35. Gómez-Laguna J, Salguero FJ, De Marco MF, Pallarés FJ, Bernabé A et al. Changes in lymphocyte subsets and cytokines during European porcine reproductive and respiratory syndrome: increased expression of IL-12 and IL-10 and proliferation of CD4(-)CD8(high). Viral Immunol 2009; 22:261–271 [View Article] [PubMed]
    [Google Scholar]
  36. Charerntantanakul W, Platt R, Johnson W, Roof M, Vaughn E et al. Immune responses and protection by vaccine and various vaccine adjuvant candidates to virulent porcine reproductive and respiratory syndrome virus. Vet Immunol Immunopathol 2006; 109:99–115 [View Article] [PubMed]
    [Google Scholar]
  37. Zhang Q, Jiang P, Song Z, Lv L, Li L et al. Pathogenicity and antigenicity of a novel NADC30-like strain of porcine reproductive and respiratory syndrome virus emerged in China. Vet Microbiol 2016; 197:93–101 [View Article] [PubMed]
    [Google Scholar]
  38. Chen N, Ye M, Li S, Huang Y, Zhou R et al. Emergence of a novel highly pathogenic recombinant virus from three lineages of porcine reproductive and respiratory syndrome virus 2 in China 2017. Transbound Emerg Dis 2018; 65:1775–1785 [View Article]
    [Google Scholar]
  39. Chen N, Cao Z, Yu X, Deng X, Zhao T et al. Emergence of novel European genotype porcine reproductive and respiratory syndrome virus in mainland China. J Gen Virol 2011; 92:880–892 [View Article] [PubMed]
    [Google Scholar]
  40. Chen N, Ye M, Xiao Y, Li S, Huang Y et al. Development of universal and quadruplex real‐time RT‐PCR assays for simultaneous detection and differentiation of porcine reproductive and respiratory syndrome viruses. Transbound Emerg Dis 2019; 66:2271–2278 [View Article]
    [Google Scholar]
  41. Trible BR, Popescu LN, Monday N, Calvert JG, Rowland RRR. A single amino acid deletion in the matrix protein of porcine reproductive and respiratory syndrome virus confers resistance to a polyclonal swine antibody with broadly neutralizing activity. J Virol 2015; 89:6515–6520 [View Article] [PubMed]
    [Google Scholar]
  42. Hao X, Li S, Chen L, Dong M, Wang J et al. Establishing a multicolor flow cytometry to characterize cellular immune response in chickens following H7N9 avian influenza virus infection. Viruses 2020; 12:1396 [View Article] [PubMed]
    [Google Scholar]
  43. Shang S, Siddiqui S, Bian Y, Zhao J, Wang CR. Nonclassical MHC Ib-restricted CD8+ T cells recognize Mycobacterium tuberculosis-derived protein antigens and contribute to protection against infection. PLoS Pathog 2016; 12:e1005688 [View Article] [PubMed]
    [Google Scholar]
  44. Tian Y, Hao Y, Dong M, Li S, Wang D et al. Development of a monoclonal antibody to pig CD69 reveals early activation of T cells in pig after PRRSV and ASFV infection. Viruses 2022; 14:1343 [View Article] [PubMed]
    [Google Scholar]
  45. Talker SC, Käser T, Reutner K, Sedlak C, Mair KH et al. Phenotypic maturation of porcine NK- and T-cell subsets. Dev Comp Immunol 2013; 40:51–68 [View Article] [PubMed]
    [Google Scholar]
  46. Gerner W, Mair KH, Schmidt S. Local and systemic T cell immunity in fighting pig viral and bacterial infections. Annu Rev Anim Biosci 2022; 10:349–372 [View Article] [PubMed]
    [Google Scholar]
  47. Reutner K, Leitner J, Müllebner A, Ladinig A, Essler SE et al. CD27 expression discriminates porcine T helper cells with functionally distinct properties. Vet Res 2013; 44:18 [View Article] [PubMed]
    [Google Scholar]
  48. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002; 2:251–262 [View Article] [PubMed]
    [Google Scholar]
  49. Sachsenberg N, Perelson AS, Yerly S, Schockmel GA, Leduc D et al. Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med 1998; 187:1295–1303 [View Article] [PubMed]
    [Google Scholar]
  50. Nazki S, Khatun A, Jeong C-G, Mattoo S ul S, Gu S et al. Evaluation of local and systemic immune responses in pigs experimentally challenged with porcine reproductive and respiratory syndrome virus. Vet Res 2020; 51: [View Article]
    [Google Scholar]
  51. Wensvoort G, Terpstra C, Pol JM, ter Laak EA, Bloemraad M et al. Mystery swine disease in The Netherlands: the isolation of Lelystad virus. Vet Q 1991; 13:121–130 [View Article] [PubMed]
    [Google Scholar]
  52. Chen N, Xiao Y, Ye M, Li X, Li S et al. High genetic diversity of Chinese porcine reproductive and respiratory syndrome viruses from 2016 to 2019. Res Vet Sci 2020; 131:38–42 [View Article]
    [Google Scholar]
  53. Guo R, Katz BB, Tomich JM, Gallagher T, Fang Y et al. Porcine reproductive and respiratory syndrome virus utilizes nanotubes for intercellular spread. J Virol 2016; 90:5163–5175 [View Article]
    [Google Scholar]
  54. Wang T, Fang L, Zhao F, Wang D, Xiao S et al. Exosomes mediate intercellular transmission of porcine reproductive and respiratory syndrome virus. J Virol 2018; 92: [View Article]
    [Google Scholar]
  55. Park C, Choi K, Jeong J, Chae C. Cross-protection of a new type 2 porcine reproductive and respiratory syndrome virus (PRRSV) modified live vaccine (Fostera PRRS) against heterologous type 1 PRRSV challenge in growing pigs. Vet Microbiol 2015; 177:87–94 [View Article]
    [Google Scholar]
  56. Choi K, Park C, Jeong J, Kang I, Park SJ et al. Comparison of commercial type 1 and type 2 PRRSV vaccines against heterologous dual challenge. Vet Rec 2016; 178:12 [View Article] [PubMed]
    [Google Scholar]
  57. Nielsen J, Bøtner A, Tingstedt J-E, Aasted B, Johnsen CK et al. In utero infection with porcine reproductive and respiratory syndrome virus modulates leukocyte subpopulations in peripheral blood and bronchoalveolar fluid of surviving piglets. Vet Immunol Immunopathol 2003; 93:135–151 [View Article] [PubMed]
    [Google Scholar]
  58. Samsom JN, de Bruin TGM, Voermans JJM, Meulenberg JJM, Pol JMA et al. Changes of leukocyte phenotype and function in the broncho-alveolar lavage fluid of pigs infected with porcine reproductive and respiratory syndrome virus: a role for CD8+ cells. J Gen Virol 2000; 81:497–505 [View Article]
    [Google Scholar]
  59. Shimizu M, Yamada S, Kawashima K, Ohashi S, Shimizu S et al. Changes of lymphocyte subpopulations in pigs infected with Porcine Reproductive and Respiratory Syndrome (PRRS) virus. Vet Immunol Immunopathol 1996; 50:19–27 [View Article] [PubMed]
    [Google Scholar]
  60. Mokhtar H, Pedrera M, Frossard J-P, Biffar L, Hammer SE et al. The non-structural protein 5 and matrix protein are antigenic targets of T cell immunity to genotype 1 porcine reproductive and respiratory syndrome viruses. Front Immunol 2016; 7:40 [View Article] [PubMed]
    [Google Scholar]
  61. Ouyang K, Hiremath J, Binjawadagi B, Shyu D-L, Dhakal S et al. Comparative analysis of routes of immunization of a live Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccine in a heterologous virus challenge study. Vet Res 2016; 47:45 [View Article] [PubMed]
    [Google Scholar]
  62. Dwivedi V, Manickam C, Patterson R, Dodson K, Murtaugh M et al. Cross-protective immunity to porcine reproductive and respiratory syndrome virus by intranasal delivery of a live virus vaccine with a potent adjuvant. Vaccine 2011; 29:4058–4066 [View Article] [PubMed]
    [Google Scholar]
  63. Canelli E, Catella A, Borghetti P, Ferrari L, Ogno G et al. Efficacy of a modified-live virus vaccine in pigs experimentally infected with a highly pathogenic porcine reproductive and respiratory syndrome virus type 1 (HP-PRRSV-1). Vet Microbiol 2018; 226:89–96 [View Article]
    [Google Scholar]
/content/journal/jgv/10.1099/jgv.0.001850
Loading
/content/journal/jgv/10.1099/jgv.0.001850
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error